Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer



Status:Active, not recruiting
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 120
Updated:1/31/2019
Start Date:August 2007
End Date:April 2020

Use our guide to learn which trials are right for you!

SOLE, Study of Letrozole Extension, A Phase III Trial Evaluating the Role of Continuous Letrozole Versus Intermittent Letrozole Following 4 to 6 Years of Prior Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone-Receptor Positive, Node Positive Early Stage Breast Cancer

RATIONALE: Estrogen can cause the growth of breast cancer cells. Letrozole may fight breast
cancer by lowering the amount of estrogen the body makes. It is not yet known which regimen
of letrozole is more effective in postmenopausal women who have received hormone therapy for
early-stage breast cancer.

PURPOSE: This randomized phase III trial is comparing two different regimens of letrozole in
preventing cancer in postmenopausal women who have received 4-6 years of hormone therapy for
hormone receptor-positive, lymph node-positive, early-stage breast cancer.

OBJECTIVES:

Primary

- Compare the disease-free survival (DFS) of postmenopausal women treated with continuous
letrozole for 5 years vs intermittent letrozole over a 5-year period.

Secondary

- Compare overall survival of patients treated with these two regimens.

- Compare distant DFS of these patients.

- Compare breast cancer-free interval of these patients.

- Compare sites of first DFS failure in these patients.

- Compare second (nonbreast) malignancies in these patients.

- Compare deaths without prior cancer events in these patients.

- Compare adverse events resulting from these two regimens.

OUTLINE: This is a multicenter study. Patients are stratified according to treatment center
and type of prior endocrine therapy (selective estrogen receptor modulators [SERMs] alone vs
aromatase inhibitors [AIs] alone vs both SERMs and AIs each for at least 1 month). Patients
are randomized to 1 of 2 treatment arms.

- Arm I: Patients receive oral letrozole daily for 5 years.

- Arm II: Patients receive oral letrozole daily for the first 9 months of years 1 through
4, followed by 12 months in year 5.

After completion of study therapy, patients are followed annually.

DISEASE CHARACTERISTICS:

- Confirmed diagnosis of prior operable, noninflammatory breast cancer meeting the
following criteria:

- Steroid hormone receptor-positive tumors (estrogen receptor and/or progesterone
receptor), determined by immunohistochemistry, after primary surgery and before
commencement of prior endocrine therapy

- Prior local treatment including surgery with or without radiotherapy for primary
breast cancer with no known clinical residual loco-regional disease

- Following primary surgery, eligible patients must have had evidence of lymph node
involvement either in the axillary or internal mammary nodes, but not
supraclavicular nodes

- Clinically disease-free

- Must have completed 4-6 years of prior adjuvant selective estrogen receptor modulators
(SERMs), aromatase inhibitors (AIs), or a sequential combination of both

- When calculating 4-6 years, neoadjuvant endocrine therapy should not be included

- No evidence of recurrent disease or distant metastatic disease

- No prior bilateral breast cancer

PATIENT CHARACTERISTICS:

- Female

- Must be postmenopausal by any of the following criteria:

- Patients of any age who have had a bilateral oophorectomy (including radiation
castration AND amenorrheic for > 3 months)

- Patients 56 years old or older with any evidence of ovarian function must have
biochemical evidence of definite postmenopausal status (defined as estradiol,
luteinizing hormone [LH], and follicle-stimulating hormone [FSH] in the
postmenopausal range)

- Patients 55 years old or younger must have biochemical evidence of definite
postmenopausal status (defined as estradiol, LH, and FSH in the postmenopausal
range)

- Patients who have received prior luteinizing-hormone releasing-hormone
(LHRH) analogues within the last year are eligible if they have definite
evidence of postmenopausal status as defined above

- Clinically adequate hepatic function

- No bone fracture due to osteoporosis at any time during the 4-6 years of prior therapy

- No prior or current malignancy except adequately treated basal cell or squamous cell
carcinoma of the skin, in situ carcinoma of the cervix or bladder, or contra- or
ipsilateral in situ breast carcinoma

- No other nonmalignant systemic diseases (cardiovascular, renal, lung, etc.) that would
prevent prolonged follow-up

- No psychiatric, addictive, or any other disorder that compromises compliance with
protocol requirements

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- More than 12 months since prior and no other concurrent endocrine SERM/AI therapy

- Any type of prior adjuvant therapy allowed including, but not limited to, any of the
following:

- Neoadjuvant chemotherapy

- Neoadjuvant endocrine therapy

- Adjuvant chemotherapy

- Trastuzumab (Herceptin®)

- Ovarian ablation

- Gonadotropin releasing hormone analogues

- Lapatinib ditosylate

- No concurrent hormone-replacement therapy, bisphosphonates (except for treatment of
bone loss), or any other investigational agent
We found this trial at
3
sites
?
mi
from
Boston, MA
Click here to add this to my saved trials
Armidale, New South Wales 2350
?
mi
from
Armidale,
Click here to add this to my saved trials
Boston, Massachusetts 02133
?
mi
from
Boston, MA
Click here to add this to my saved trials